|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
To better understand the potential impact of these mutant amino acids on protease function and cancer progression, we established a bioinformatics approach to assessing the impact of melanoma mutants, among a previously defined set of extracellular matrix (ECM) structural proteins, on the sensitivity of matrix metalloproteinase-2 (MMP2), extensively associated with melanoma.
|
31019293 |
2019 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We show that METTL3 is upregulated in human melanoma and plays a role in invasion/migration through MMP2.
|
30762711 |
2019 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Melanoma metastasis requires migration and invasion of the malignant tumour cells driven by proteolytic remodelling of the extracellular matrix (ECM) executed by matrix metalloproteinases (MMPs), particularly MMP-2 and MMP-9.
|
31020875 |
2019 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
IL-33/ST2 Axis Regulates Vasculogenic Mimicry via ERK1/2-MMP-2/9 Pathway in Melanoma.
|
30928981 |
2019 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We used a bioinformatics approach to assess the impact of amino acid (AA) substitutions on the sensitivity of CECMPs to proteases relevant to melanoma and on the binding affinities for HLA class I. CECMP peptides with AA substitutions overwhelmingly reflect increased sensitivity to proteases implicated in melanoma development (MME, CTSS, MMP2, CTSD, CTSL) in comparison to the wild-type peptide sequences.
|
29047110 |
2018 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Down-regulating Myoferlin inhibits the vasculogenic mimicry of melanoma via decreasing MMP-2 and inducing mesenchymal-to-epithelial transition.
|
29164766 |
2018 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
An engineered PD-1-based and MMP-2/9-oriented fusion protein exerts potent antitumor effects against melanoma.
|
30021673 |
2018 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Melanoma A-2058 demonstrated strong expression of MMP-2 and slight expression of MMP-9.
|
28440509 |
2017 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Therefore, CA can be characterized as a novel V-ATPase inhibitor for the treatment of melanoma that may inhibit invasion and metastasis by downregulating the expression of MMP-2 and -9.
|
29113270 |
2017 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The findings indicate that NCTD inhibits tumor growth and VM formation of melanoma both <i>in vitro</i> and <i>in vivo</i> by suppressing matrix metalloproteinase-2 expression.
|
28454306 |
2017 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Kinase activation led to increased MMP-2 and MT1-MMP expression and melanoma cell migration induced by hHK-1.
|
27458061 |
2016 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Induction of MDA-9/syntenin in melanoma was found to occur in a thrombin-independent signaling pathway and involves the PAR-1/c-Src/Rho GTPases Rac1 and Cdc42/c-Jun N-terminal kinase axis resulting in the activation of paxillin, NF-κB, and matrix metalloproteinase-2 (MMP-2).
|
25505176 |
2015 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, the prognostic value of MMP-2 and Ki-67 via immuno-staining in head and neck melanoma is investigated.
|
25313763 |
2015 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The melanoma cell lines showed different growth patterns in the brain, and these differences were associated with differences in expression of the angiogenic factors VEGF-A and IL-8 and the matrix metalloproteinases MMP-2 and MMP-9.
|
26667022 |
2015 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Importantly, knocking down CD147 attenuates MMP2 response to hypoxia in melanoma cell lines.
|
24090196 |
2014 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Both melanoma cell invasion and MMP-2 activity increased and decreased with EIF5A2 overexpression and knockdown, respectively.
|
24178756 |
2014 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
A novel matrix metalloproteinase-2 inhibitor triazolylmethyl aziridine reduces melanoma cell invasion, angiogenesis and targets ERK1/2 phosphorylation.
|
24246091 |
2014 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, Pin1 inhibition also resulted in decreased phosphorylation of Akt and repressed expression of C-Jun N-terminal kinase and pro-matrix metalloproteinase 2, which were associated closely with the development of melanoma.
|
23067222 |
2013 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The caspase-3-mediated promotion of melanoma cell motility may be because of the cleavage of matrix metalloproteinase-2.
|
23695439 |
2013 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
This study indicates that microcystin-LR can act as a NF-κB activator to promote MMP-2/-9 expression and melanoma cell invasion, which deserves more environmental health concerns.
|
22992115 |
2012 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Activation of metalloproteinase (MMP) 2 expression greatly contributed to the BRG1 induced increase in melanoma invasiveness.
|
20969766 |
2010 |
|
melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Only 4 of the breast/colorectal 'hill' type CAN genes (SMAD4, MYO18B, NAV3 and MMP2) were also mutated in melanoma and pancreatic carcinoma, while none was altered in glioblastoma.
|
19058223 |
2009 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Concomitant decreases in vascular endothelial growth factor, interleukin-8, and matrix metalloproteinase-2 expression levels, as well as decreased blood vessel density (CD31), were found in tumor samples from PAR-1 siRNA-treated mice, suggesting that PAR-1 is a regulator of melanoma cell growth and metastasis by affecting angiogenic and invasive factors.
|
18974154 |
2008 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
More than 90% tumors expressed alpha6a, beta1, beta3 and beta6 (non-melanoma), and alpha5a, alpha6a and MMP2 (MM).
|
18251742 |
2008 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
LHGDN |
Interestingly, male patients with a melanoma with overexpression of MMP-2 showed a 10-year disease-specific survival of only 41% compared with 77% in other male patients (P = .003).
|
18187184 |
2008 |